The aim of this review is to defne the role of the combined dienogest (DNG)/estradiol valerate (E2V) contraceptive pill, in terms of biochemistry, metabolic and pharmacological effects and clinical application as well. E2V is the esterifed form of 17β-estradiol (E2), while dienogest is a fourth-generation progestin with a partial antiandrogenic effect. The cycle stability is achieved with 2 to 3 mg DNG, supporting contraceptive effcacy. In this new oral contraceptive, E2V is combined with DNG in a four-phasic dose regimen (the frst two tablets contain 3 mg E2V; the next fve tablets include 2 mg E2V + 2 mg DNG, followed by 17 tablets with 2 mg E2V + 3 mg DNG; followed by two tablets with 1 mg E2V only, and fnally two placebo tablets). Duration and intensity of scheduled withdrawal bleeding are lower with this contraceptive pill, whereas the incidence and the intensity of intra-cyclic bleeding are similar to the other oral contraceptive. With this new pill the levels of high density lipoprotein increased, while the levels of prothrombin fragment 1 + 2 and D-dimer remained relatively unchanged; the levels of sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin increased. The most frequently reported adverse events are: breast pain, headache, acne, alopecia, migraine, increase of bodyweight. The satisfaction rate is about 79.4%. © 2010 Guida et al, publisher and licensee Dove Medical Press Ltd.
CITATION STYLE
Guida, M., Bifulco, G., di Spiezio Sardo, A., Scala, M., Sosa, L. M., & Nappi, F. C. (2010). Review of the safety, efficacy and patient acceptability of the combined dienogest/ estradiol valerate contraceptive pill. International Journal of Women’s Health. https://doi.org/10.2147/IJWH.S6954
Mendeley helps you to discover research relevant for your work.